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Abstract: DNA methylation is a key epigenetic mechanism that plays a significant role in regulating gene activity 
during cardiac development. Congenital heart defects (CHD) are one of the most common abnormalities occurring in 
40% -60% of cases with Down syndrome (DS). The main aim of this study was to establish the association of long 
interspersed nucleotide element-1 (LINE-1) DNA methylation in children with DS and the presence of CHD. The 
LINE-1 DNA methylation was investigated in peripheral blood lymphocytes on a sample of 42 people with DS by 
quantification of LINE-1 methylation using the MethyLight method. No significant differences in global DNA 
methylation were found according to the presence of CHD (P=1.000), but values of LINE-1 DNA methylation were 
significantly influenced by gender (R2=19.1%; P=0.025). Significant probability of 19.1% was found in women with 
DS who had lower LINE-1 DNA methylation values than DS male. Gender was a statistically significant predictor of 
LINE-1 DNA methylation, although the difference was not statistically significant, female subjects had lower LINE-1 
DNA methylation values (P=0.068). Further research will clarify the role of lower LINE-1 DNA methylation in the 
formation of CHD among DS females. 
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INTRODUCTION 
 
Congenital heart defects (CHD) are among the most 
common birth anomalies, as well as medically 
indicated breaks of pregnancy.1 CHD may occur as 
isolated malformations or combined with other 
extracardial malformations.2, 3 They are caused by 
incomplete heart development during the embryonic 
period.4, 5 Chromosomal abnormalities occur in 5-10%, 
and genetic changes in 3-5% of cases with CHD.6 
Approximately 2% of CHD cases occur during 
embryonic development due to alcohol toxicity, and 
drugs such as lithium, thalidomide, some antiepileptic, 
as well as the exposure of the mother to x-rays.7 It is 
believed that 85% of CHD has multifactorial etiology 
and is the result of interaction between mother and 
child genes as well as numerous external factors that 
affect the cardiac development of a fetus.8-12 
Epigenetic mechanisms contribute to the regulation of 
many physiological processes during development. As 
one of the epigenetic mechanisms, aberrant DNA 
methylation has been clearly associated with CHD.13 
DNA methylation by the addition of a methyl group on 
cytosine alters the structure of the DNA and could have 
an impact on gene expression. Several epidemiological 
studies have reported that the global methylation level 
could be a determinant risk factor for CHD, but the 
results have been inconsistent.14-16 About 55% of the 
human genome is made up of repetitive elements. 
Useful surrogate marker for estimating global genomic 
DNA metylation are LINE-1, which are highly 
repeated and widely interspersed human 
retrotransopsones.
17
 In addition, LINE-1 DNA 
hypomethylation is associated with the development of 
CHD, and particularly of septal defects.18, 19 
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Down syndrome (DS) is the most common cause of 
mental retardation in humans, resulting from trisomy of 
the chromosome 21.20 Clinical sings of DS are well- 
known, typical craniofacial dysmorphic features and 
intellectual disabilities are presents in all cases, and 
other clinical features occur in a certain, greater or 
lower percentage of DS patients.21 CHD are one of the 
common abnormalities occurring in 40-60% of DS 
cases. Most commonly these are septal defects, 
including atrial defect, ventricular septal defect, 
complete atrioventricular canal, tetralogy Fallot, open 
ductus Botalli and other cardiovascular 
malformations.21, 22 Causes of clinical differences are 
still unknown and are the focus of many studies. 
Evidence shows that phenotypic variability in DS can 
contribute to various genetic and epigenetic factors 
such as gene expression variability, transcriptional 
factor activity encoded at chromosome 21 or elsewhere 
in the genome, variable number of repeating sequences, 
activity of different regulatory RNA molecules and 
DNA methylation.23 It is known that genes on 
chromosome 21 can be classified into various 
functional categories.24 Therefore, apart from the 
primary effect such as increased gene expression on 
chromosome 21, there is a secondary effect of trisomy 
21 on gene expression located elsewhere in the 
genome.25-27 In addition, epigenetic changes are 
influenced by external factors; some of them are 
associated with the onset of CHD.28 Thus, certain types 
of CHD in DS are associated with smoking tobacco 
intake and insufficient intake of folate in the 
preconception period of the mother, as well as the 
polymorphisms of genes involved in the metabolism of 
folate and the changed concentrations of metabolites 
involved in the metabolism of folate in mothers and 
persons with DS.28, 29 Obermann-Borst et al measured 
the concentration of biometric methylation 
concentration in the blood of children with CHD and 
showed a significantly higher concentration of S- 
adenosylhomocysteine (SAH) and a lower ratio of S- 
adenosylmethionine (SAM) / S-adenosylhomocysteine 
(SAM / SAH) in the DS group, which means that DNA 
hypomethylation had arisen. Similarly, in the mothers 
of DS and CHD children, a significantly elevated level 
of total homocysteine and SAH was found, as well as a 
significantly lower ratio of SAM / SAH compared to 
the control group.30 
Considering that DS is commonly associated with 
CHDs that have a common pathogenic mechanism of 
occurrence, and that in many cases septal defects are 
present, trisomy 21 is also a good model for 
determining the association of LINE-1 DNA 
methylation and the development of cardiovascular 
defects. Therefore, the main aim of this study was to 
establish the association of LINE-1 DNA methylation 
in children with DS and the presence of CHD. 
MATERIAL AND METHODS 
 
The study included 42 people with a regular type of 
trisomy 21. Subjects were collected in collaboration 
with Down syndrome associations in the Republic of 
Croatia (Rijeka, Split, Pula, Osijek, Zadar, Karlovac, 
Čakovec and Zagreb) and the Clinic of Gynecology 
and obstetrics, Clinical Hospital Center Rijeka. Parents 
and guardians of all participants were familiar with the 
purpose and methodology of research and gave their 
written consent. The Ethics Committee for Biomedical 
Research at the Faculty of Medicine, University of 
Rijeka approved the research. 
 
 
Isolation of genomic DNA 
 
Genomic DNA was isolated from peripheral blood (3- 
5ml) obtained by venipuncture using FlexiGene DNA 
Kit (QIAGEN GmbH, Hilden, Germany) according to 
the protocol specified by the manufacturer. 
 
 
Determination of LINE-1 DNA Methylation by 
MethyLight 
 
MethyLight is a quantitative real-time polymerase 
chain reaction (qPCR), high-throughput and high 
specificity method for detecting sequences that are 
methylate. Bisulphite modification produces 
differences in DNA depending on the presence of 
methylation. Those differences are precisely detected 
by the MethyLight method, after amplification of the 
modified DNA, by binding specific fluorescently 
labeled probe sites to methylated DNA. LINE-1 DNA 
methylation was determined by quantification of LINE- 
1 methylation using the modified MethyLight method. 
This method only detects fully methylated and 
completely unmethylated LINE-1 sequences, while 
partial LINE-1 methylation cannot be detected. 
Methodology and protocols have previously been 
described in detail.17, 18, 31 
Statistical analyses were performed using MedCalc for 
Windows (MedCalc Software, Ostend, Belgium) and 
Statistics for Windows (StatSoft, Inc., Tulsa, USA). 
Statistical significance was considered at P<0.05. 
 
 
RESULTS AND DISCUSSION 
 
In this study, the analysis of LINE-1 DNA methylation 
was performed on a sample of 42 individuals with DS, 
20 males and 22 females. The analysis was done on 
DNA isolated from blood, since DNA methylation is 
known to differ quite dramatically between tissues. The 
median of the ages was 14 years [0.08-48]. CHDs were 
present in 36% (15/42) of participants. The remaining 
64% (27/42) of participants were without CHDs. This 
is lower than the 40-60% documented in literature.21, 22
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Table 1. LINE-1 DNA methylation in Down syndrome DS 








[95.20 - 99.68] 
*DS-CHD- 
99.02 




The main reason for this discrepancy is probably the 
small number of participants or regional geographic 
influences. Furthermore, we observed higher 
frequencies of CHDs among females (53%) than males 
(47%) but without statistical significance (P=0.409). A 
predominance of males among children with CHDs in 
general has been previously observed, but among 
children with DS and CHDs there is a higher 
proportion of females.22, 32, 33        
Ventricular septal defect alone also showed a higher 
frequency in the female gender with DS than in the 
general population.32 It is known that sex differences in 
cardiovascular diseases result from a complex 
interaction between genetic, hormonal and 
environmental factors that provide a profile of 
individual risk and phenotypic presentation. 
No significant differences were found between DS 
participants according to the presence of CHD in 
LINE-1 DNA methylation (Table 1). A stepwise 
multiple regression analysis for LINE-1 DNA 
methylation was performed and independent variables 
included age, gender, MTHFR C677T genotype and  
the presence of CHD. The gender was the only 
statistically significant predictor of LINE-1 DNA 
methylation variability. It was established with a 
statistically significant probability of 19.1% (β=-0.437, 
R2=0.191, P=0.025) that DS females would have lower 
LINE1 DNA methylation than DS males (P<0.05), 
despite the fact that LINE-1 DNA methylation values 




Table 2. LINE-1 DNA methylation in Down syndrome 





LINE-1 DNA methylation (%) 
Median 
Male 22 (52) 
99.06 
[95.66 – 99.95] 
Female 20 (48) 
98.31 
[95.20 – 99.78] 
N- number of individuals; Mann-Whitney P=0.068 
 
 
In most studies in which LINE-1 DNA methylation 
was determined by quantification of LINE-1 
methylation in peripheral blood lymphocytes, a lower 
global DNA methylation status was found in female 
subjects.34 The cause for this gender specific alteration 
in global DNA methylation is not clear. One of the two 
chromosomes in women is greatly methylated and 
transcriptionally inactivated. It has been suggested that 
X chromosome inactivation may reduce resources 
essential for proper methylations of autosomal loci. 
Lower levels of global methylation in women may also 
be due to altered levels of dietary folate or other one- 
carbon nutrients in men and women. Women may also 
have a different folate requirement than men because of 
regular red blood cells loss through menstruation.35- 37 
In conclusion, we found significantly lower LINE-1 
DNA methylation in peripheral blood among DS 
females. The associations are unlikely to be mediated 
by body composition and other risk factors such as 
dietary, physical activity, lifestyle. The biological 
mechanisms underlying these differences warrant 
further investigation. To explain the possibility that 
lower LINE-1 DNA methylation in DS females has a 
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